Article
Oncology
Yuchao Wang, Li Li, Chunhua Xu
Summary: Nanoparticle albumin bound paclitaxel (Nab-P) showed good efficacy and safety as a third-line treatment for relapsed small cell lung cancer (SCLC), with an objective response rate of 24.32% and disease control rate of 81.08%. The main adverse reactions were gastrointestinal reactions, bone marrow suppression, and fatigue.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2021)
Article
Nanoscience & Nanotechnology
Jing Huang, Hongqi Huo, Mulan Chen, Lili Wang, Nani Li, Zhijian Huang, Lin Yang
Summary: This study compared the antitumor efficacy and toxicity of nab-paclitaxel and paclitaxel, and found that nab-paclitaxel was more effective in inhibiting cancer cell growth, inducing apoptosis, and causing G1 arrest in the cell cycle.
SCIENCE OF ADVANCED MATERIALS
(2022)
Article
Oncology
Satoshi Shoji, Satoru Miura, Satoshi Watanabe, Aya Ohtsubo, Koichiro Nozaki, Yu Saida, Kosuke Ichikawa, Rie Kondo, Tomohiro Tanaka, Kenichi Koyama, Hiroshi Tanaka, Masaaki Okajima, Tetsuya Abe, Takeshi Ota, Takashi Ishida, Masato Makino, Akira Iwashima, Kazuhiro Sato, Naoya Matsumoto, Hirohisa Yoshizawa, Toshiaki Kikuchi
Summary: This study evaluated the efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy in previously treated patients with advanced non-small cell lung cancer. Nab-paclitaxel showed good tolerability and anti-tumor activity. There was a low degree of concordance in grading chemotherapy-induced peripheral neuropathy between physicians and patients.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Article
Biotechnology & Applied Microbiology
Xiaokang Shen, TianMing Chen, Nianlong Liu, Bo Yang, GuoDong Feng, Pengcheng Yu, Chuanfei Zhan, Na Yin, YuHuang Wang, Bin Huang, Shilin Chen
Summary: This study compares the clinical value of MRI-guided microwave ablation (MRI-MWA) and CT-guided microwave ablation (CT-MWA) in non-small cell lung cancer (NSCLC). The results show that MRI-MWA group has advantages in needle placement accuracy, microwave ablation time, and overall complication rate compared to the CT-MWA group. Additionally, the MRI-MWA group has a longer progression-free survival. These findings demonstrate the clinical efficacy of MRI-guided MWA in NSCLC patients.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Yan Li, Xiang Chen, Qiannan Zhu, Rui Chen, Lu Xu, Shuo Li, Xiaoqing Shi, Haiping Xu, Yinggang Xu, Weiwei Zhang, Xiaofeng Huang, Xiaoming Zha, Jue Wang
Summary: The study compared the efficacy and safety of 2-weekly nanoparticle albumin-bound paclitaxel (nP) and 3-weekly docetaxel regimens as neoadjuvant systemic therapy for breast cancer. The nP group achieved higher pathological complete response rates, especially in patients with triple-negative tumor cells and high Ki67 levels. However, grades 3-4 peripheral sensory neuropathies were more frequent in the nP group.
Article
Biotechnology & Applied Microbiology
Weiwei Zhang, Yinggang Xu, Xiaoqing Shi, Xiaofeng Huang, Rui Chen, Haiping Xu, Wenjie Shi, Xinyu Wan, Ye Wang, Jinzhi He, Cuiying Li, Jue Wang, Xiaoming Zha
Summary: This study retrospectively compared the efficacy and safety of two potential neoadjuvant systemic treatment drugs, liposomal paclitaxel (Lps-P) and nanoparticle albumin-bound paclitaxel (Nab-P), in breast cancer. The results showed that more participants who received Nab-P had no signs of cancer in their breast and axillary lymph nodes than participants who received Lps-P. Although Nab-P can cause a higher incidence and severity of peripheral sensory neuropathy (PSN), most symptoms are temporary and reversible. In conclusion, Nab-P might be superior to Lps-P for neoadjuvant systemic treatment of breast cancer.
Review
Multidisciplinary Sciences
Nittiya Suwannasom, Netsai Sriaksorn, Chutamas Thepmalee, Chonthida Thephinlap, Patcharawan Tanamatayarat, Krissana Khoothiam, Hans Baeuemler, Nat Na-Ek
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in advanced non-small cell lung cancer. The results showed that nab-paclitaxel significantly improved the OR rate and PR rate compared to the control group, especially in squamous cell carcinoma and as a second-line treatment. However, there was insufficient evidence on the reduction of adverse events with nab-paclitaxel treatment and biases in study selection and detection may have influenced the results.
Article
Medicine, General & Internal
Hajime Oi, Toshiaki Matsuda, Tomoki Kimura, Masahiro Morise, Yasuhiko Yamano, Toshiki Yokoyama, Kensuke Kataoka, Yasuhiro Kondoh
Summary: Weekly nab-PTX and PTX have similar efficacy and safety profiles for relapsed SCLC. In this retrospective study, there were no significant differences in response rate, median progression-free survival, and overall survival between the two treatment options.
Review
Oncology
Zhichao Tian, Weitao Yao
Summary: This review compares the similarities and differences among nab-paclitaxel, paclitaxel, and docetaxel, and summarizes the efficacy of nab-paclitaxel in sarcomas and non-sarcoma malignancies based on clinical trials.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Zhichao Tian, Shuping Dong, Yang Yang, Shilei Gao, Yonghao Yang, Jinpo Yang, Peng Zhang, Xin Wang, Weitao Yao
Summary: Nab-paclitaxel plus PD-1 inhibitor is a promising treatment regimen for advanced soft tissue sarcoma, showing potential efficacy and safety. Patients with angiosarcoma may have better outcomes compared to other histological subtypes, and those who experienced more adverse events may have longer PFS.
Article
Pharmacology & Pharmacy
Yanhao Zhang, Ji Wang, Hanlei Xing, Chao Liu, Xinsong Li
Summary: In this study, a redox-responsive paclitaxel-pentadecanoic acid prodrug conjugate embedded human serum albumin nanoparticles (HPTX NPs) were developed for cancer chemotherapy. The HPTX NPs exhibited high drug loading, longer drug retention, more effective tumor growth inhibition, and lower systemic toxicity.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Nanoscience & Nanotechnology
Wenjie Shi, Xinyu Wan, Ye Wang, Jinzhi He, Xiaofeng Huang, Yinggang Xu, Weiwei Zhang, Rui Chen, Lexin Wang, Ran Zheng, Lingjun Ma, Xuan Li, Lu Xu, Xiaoming Zha, Jue Wang
Summary: This study compared the efficacy of different paclitaxel formulations in neoadjuvant systemic therapy for HER2-low-positive and HER2-zero breast cancers. The results showed that Nab-P had a significantly higher pathological complete response rate in HER2-low-positive patients compared to other paclitaxel formulations. However, there was no significant difference in the response rate among the four paclitaxel groups in HER2-zero patients. The NST regimen containing Nab-P could be a promising treatment option for HER2-low-positive breast cancer.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
(2023)
Article
Oncology
Hui Jiang, Qiaoqiao Li, Baoqing Chen, Mian Xi, Kanjiebubi Makelike, Shiliang Liu, Yonghong Hu, Yujia Zhu
Summary: This study aimed to evaluate the safety, dose-limiting toxicity, maximum tolerated dose, and preliminary effect of nanoparticle albumin-bound paclitaxel in combination with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. The results showed that this treatment regimen was effective and well-tolerated for patients with locally advanced esophageal squamous cell carcinoma.
Article
Oncology
Xiaozhun Huang, Chunling Wang, Teng Ma, Zhangkan Huang, Houhong Zhou, Lin Xu, Renjie Zhang, Jianjun Zhao, Yefan Zhang, Zhen Huang, Lin Shao, Yang Wang, Fan Yang, Xu Che
Summary: For patients with pancreatic squamous cell carcinoma, combination therapy of cisplatin and nanoparticle albumin-bound paclitaxel may offer a favorable clinical activity and survival advantage, making it a potential therapeutic option.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yu Mei, Min Shi, Zhenglun Zhu, Hong Yuan, Chao Yan, Chen Li, Tienan Feng, Min Yan, Jun Zhang, Zhenggang Zhu
Summary: The prognosis of stage III gastric cancer is poor, and there is currently no clear conclusion on chemotherapy regimens for stage IIIC GC. The Dragon-VII trial is designed to evaluate the safety and efficacy of the combination of Nab-PTX, S-1, and sintilimab in treating stage IIIC gastric cancer.
Article
Medicine, Research & Experimental
Takuya Inoue, Hironori Takagi, Yuki Owada, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroshi Yokouchi, Kenya Kanazawa, Katsuya Ohbuchi, Takahisa Fukushima, Mitsuru Munakata, Hiroyuki Suzuki
Article
Oncology
Takumi Yamaura, Junji Ezaki, Naoyuki Okabe, Hironori Takagi, Yuki Ozaki, Takuya Inoue, Yuzuru Watanabe, Mitsuro Fukuhara, Satoshi Muto, Yuki Matsumura, Takeo Hasegawa, Mika Hoshino, Jun Osugi, Yutaka Shio, Satoshi Waguri, Hirosumi Tamura, Jun-Ichi Imai, Emi Ito, Yuka Yanagisawa, Reiko Honma, Shinya Watanabe, Hiroyuki Suzuki
Article
Cardiac & Cardiovascular Systems
Yuki Matsumura, Yuki Owada, Takuya Inoue, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Takeo Hasegawa, Mika Hoshino, Jun Osugi, Mitsunori Higuchi, Hiroyuki Suzuki
INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY
(2017)
Article
Oncology
Kazuyoshi Takeda, Kazutaka Kitaura, Ryuji Suzuki, Yuki Owada, Satoshi Muto, Naoyuki Okabe, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Takuya Tsunoda, Ko Okumura, Hiroyuki Suzuki
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2018)
Article
Oncology
Yuki Owada-Ozaki, Satoshi Muto, Hironori Takagi, Takuya Inoue, Yuzuru Watanabe, Mitsuro Fukuhara, Takumi Yamaura, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Ohsugi, Mika Hoshino, Yutaka Shio, Hideaki Nanamiya, Jun-ichi Imai, Takao Isogai, Shinya Watanabe, Hiroyuki Suzuki
JOURNAL OF THORACIC ONCOLOGY
(2018)
Article
Oncology
Yuki Ozaki, Satoshi Muto, Hironori Takagi, Masayuki Watanabe, Takuya Inoue, Mitsuro Fukuhara, Takumi Yamaura, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Ohsugi, Mika Hoshino, Yutaka Shio, Daisuke Tanaka, Hideaki Nanamiya, Jun-ichi Imai, Takao Isogai, Shinya Watanabe, Hiroyuki Suzuki
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2020)
Article
Oncology
Takumi Yamaura, Satoshi Muto, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Yuki Ozaki, Takuya Inoue, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki
Article
Oncology
Satoshi Muto, Yuki Ozaki, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hideaki Nanamiya, Jun-Ichi Imai, Takao Isogai, Shinya Watanabe, Hiroyuki Suzuki
Summary: In patients with non-small cell lung cancer, the expression of beta-catenin was negatively associated with the infiltration of CD11c(+) cells and cytotoxic T cells in tumor tissues, and correlated with a poorer prognosis.
Article
Oncology
Hironori Takagi, Songji Zhao, Satoshi Muto, Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Hikaru Yamaguchi, Hayato Mine, Masayuki Watanabe, Yuki Ozaki, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Ryuzo Kanno, Miho Aoki, Chengbo Tan, Saki Shimoyama, Shigeo Yamazaki, Hajime Kikuchi, Jun Sakakibara-Konishi, Satoshi Oizumi, Masao Harada, Kenji Akie, Fumiko Sugaya, Yuka Fujita, Kei Takamura, Tetsuya Kojima, Osamu Honjo, Yoshinori Minami, Masaharu Nishimura, Hirotoshi Dosaka-Akita, Koji Nakamura, Akihiro Inano, Hiroshi Isobe, Hiroyuki Suzuki
Summary: This study confirmed the expression of DLK1 in SCLC and NSCLC, suggesting a potentially different clinical significance in the two lung cancer types. The results also indicated the possibility of DLK1 as a new therapeutic target, including RIT, in SCLC, as demonstrated in cell and animal experiments.
Article
Oncology
Mitsuro Fukuhara, Satoshi Muto, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki
Summary: This study found that high expression of tertiary lymphoid structure (TLS) is associated with a good prognosis in patients with non-small cell lung cancer, while a low neutrophil to lymphocyte ratio and few antigen-presenting cells in peripheral blood indicate the presence of TLS in the tumor microenvironment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Biochemistry & Molecular Biology
Satoshi Muto, Akio Enta, Yoshiyuki Maruya, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Kazuyuki Hamada, Hiroyuki Suzuki
Summary: Lung cancer is a major cause of death globally. The standard treatment for advanced non-small-cell lung cancer (NSCLC) without certain gene mutations involves a combination of immunotherapy and chemotherapy or immunotherapy and another type of antibody. Although combination treatment can reduce disease progression, only about half of the patients respond long-term. Therefore, it is important to understand the mechanisms of resistance to immunotherapy. One potential mechanism is the Wnt/beta-catenin signaling pathway. This review summarizes the current knowledge on resistance mechanisms in NSCLC and other cancers, focusing on the role of Wnt/beta-catenin signaling. Therapeutic approaches to overcome these resistance mechanisms are also discussed.
Review
Medicine, General & Internal
Takeo Hasegawa, Yuki Ozaki, Takuya Inoue, Yuzuru Watanabe, Mitsuro Fukuhara, Takumi Yamaura, Satoshi Muto, Naoyuki Okabe, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki
JOURNAL OF MEDICAL CASE REPORTS
(2019)
Article
Medicine, General & Internal
Mitsunori Higuchi, Hironori Takagi, Yuki Ozaki, Takuya Inoue, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Yutaka Shio, Hiroyuki Suzuki
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
(2018)
Article
Oncology
Satoshi Muto, Hironori Takagi, Yuki Owada, Takuya Inoue, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki
ANTICANCER RESEARCH
(2017)